Related Experiment Video

Updated: Jul 13, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Enhanced spontaneous thrombolysis: a new therapeutic challenge

I B Kovacs1, D A Gorog, J Yamamoto

  • 1St. Bartholomew's Hospital Medical School, London, UK.

Journal of Thrombosis and Thrombolysis
|May 10, 2006
PubMed

Insights

Reduced spontaneous thrombolysis, the body's clot-dissolving ability, is a neglected risk factor for heart attacks. A new test may identify at-risk individuals and guide treatments for coronary heart disease.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Spontaneous thrombolysis is a key endogenous defense against arterial thrombotic occlusion, crucial in myocardial infarction and acute coronary events.
  • Coronary heart disease (CHD) is increasingly preventable through novel therapies and lifestyle interventions, yet reduced fibrinolytic activity remains an underappreciated risk factor.
  • Existing knowledge on the fibrinolytic effects of common CHD medications (antiplatelets, biguanides, antihypertensives) is limited and contradictory.

Purpose of the Study:

  • To highlight the clinical significance of spontaneous thrombolysis in cardiovascular disease.
  • To address the lack of a comprehensive assay for spontaneous thrombolysis.
  • To explore the potential of a new measurement technique for spontaneous thrombolysis.

Main Methods:

  • A recently developed technique enables the measurement of spontaneous thrombolysis.
  • This method assesses the lysis of autologous platelet-rich thrombi without added plasminogen activators.
  • It differs from traditional assessments of plasma or whole blood fibrinolysis.

Main Results:

  • Early findings indicate the test's potential clinical utility.
  • The assay may help identify individuals at risk for fatal cardiac events.
  • It could also reveal new therapeutic strategies or lifestyle modifications to enhance spontaneous thrombolytic activity.

Conclusions:

  • Reduced spontaneous thrombolytic activity is a significant, yet overlooked, risk factor for ischemic cardiovascular events.
  • A novel assay for measuring spontaneous thrombolysis shows promise for clinical application.
  • This test could aid in risk stratification and the development of novel treatments for coronary heart disease.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model06:16

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model

Published on: April 19, 2024

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...